Medpage Today on MSN5mon
Nipocalimab Shows Sustained Efficacy in Myasthenia Gravis
SAVANNAH, Ga. -- Investigational nipocalimab lessened disease severity in generalized myasthenia gravis (gMG), the phase III ...
The American Journal of Managed Care25d
How Nipocalimab Targets Unmet Needs in Autoimmune Care
In part 4 of our interview, we learn more about nipocalimab’s safety profile and how this investigative agent might address unmet needs for patients with generalized myasthenia gravis.
pharmaphorum8d
J&J adds another string to nipocalimab bow with gMG data
Johnson & Johnson has reported new phase 3 data with its FcRn blocker nipocalimab in generalised myasthenia gravis (gMG), pointing to data that it says differentiates it from other drugs in the class.
Hosted on MSN1mon
Johnson & Johnson reports progress on nipocalimab
SPRING HOUSE, Pa. - Johnson & Johnson (NYSE: NYSE:JNJ) has released new data on nipocalimab, an investigational drug with potential to treat diseases driven by immunoglobulin G (IgG) antibodies.
Nasdaq1mon
Johnson & Johnson's Nipocalimab Shows Promising Results For IgG-Driven Diseases; Stock Up
(RTTNews) - Johnson & Johnson (JNJ), on Thursday announced the publication of new data on nipocalimab, an investigational drug designed to treat IgG-driven alloantibody and autoantibody diseases.
Business Insider1mon
Johnson & Johnson publishes nipocalimab study results in The Lancet Neurology
Johnson & Johnson announced The Lancet Neurology has published results from the pivotal Phase 3 study of nipocalimab, an investigational FcRn blocker, evaluated in a broad population of antibody ...